- ICH GCP
- Registro degli studi clinici negli Stati Uniti
- Sperimentazione clinica NCT05502341
Study to Compare Bictegravir/Lenacapavir Versus Current Therapy in People With HIV-1 Who Are Successfully Treated With a Complicated Regimen (ARTISTRY-1) (ARTISTRY-1)
Uno studio operativo di fase 2/3 randomizzato, in aperto, multicentrico, con controllo attivo per valutare la sicurezza e l'efficacia di Bictegravir/Lenacapavir rispetto al regime basale stabile nelle persone con soppressione virologica con HIV-1 in regimi di trattamento complesso stabile
The goal of this clinical study is to learn more about the effects of switching to the study drugs, bictegravir (BIC) plus lenacapavir (LEN), versus current therapy (Phase 2) and BIC/LEN fixed-dose combination (FDC) versus current therapy (Phase 3) in people living with HIV (PWH).
Panoramica dello studio
Stato
Condizioni
Intervento / Trattamento
Tipo di studio
Iscrizione (Effettivo)
Fase
- Fase 2
- Fase 3
Contatti e Sedi
Luoghi di studio
-
-
-
Buenos Aires, Argentina, 1202
- Fundación Huésped
-
Buenos Aires, Argentina, 1072
- Hospital General de Agudos J.M Ramon Mejia
-
Buenos Aires, Argentina, 1425
- Helios Salud
-
-
-
-
New South Wales
-
Darlinghurst, New South Wales, Australia, 2010
- St.Vincent's Hospital Sydney
-
Darlinghurst, New South Wales, Australia, 2011
- Taylor Square Private Clinic
-
Sydney, New South Wales, Australia, 2010
- Holdsworth House Medical Practice
-
-
Victoria
-
Melbourne, Victoria, Australia, 3004
- Alfred Health
-
-
-
-
-
Decarie Montreal, Canada, H4A 3J1
- Chronic Viral Illness Service / McGill University Health Centre (MUHC)
-
Montreal, Canada, H2L 0B1
- Clinique Medicale du Quartier Latin
-
Ottawa, Canada, K1H 8L6
- The Ottawa Hospital - General Campus
-
Regina, Canada, S4P 0W5
- ID Clinic
-
Toronto, Canada, M5G 1K2
- Maple Leaf Research
-
Vancouver, Canada, V6Z 2T1
- Spectrum Health
-
-
-
-
-
Daegu, Corea del Sud, 41944
- Kyungpook National University Hospital
-
Daejeon, Corea del Sud, 35015
- Chungnam National University Hospital
-
Seoul, Corea del Sud, 06591
- The Catholic University of Korea Seoul St. Mary's Hospital
-
Seoul, Corea del Sud, 03722
- Yonsei University Severance Hospital
-
-
-
-
-
Nice, Francia, 6202
- CHU Nice-Hôpital l'Archet
-
Paris, Francia, 75010
- Hospital Saint Louis
-
Paris, Francia, 75018
- Groupe Hospitalier Bichat Claude Bernard
-
Paris, Francia, 75651
- Höpital de la Pitié Salpêtrière
-
-
-
-
-
Berlin, Germania, 10439
- zibp Zentrum für Infektiologie Berlin Prenzlauer Berg GmbH
-
Bonn, Germania, 53127
- Universitatsklinikum Bonn
-
Frankfurt, Germania, 60596
- Infektio Research GmbH & Co.KG
-
Hamburg, Germania, 20146
- ICH Study Center GmbH & Co. KG
-
München, Germania
- MVZ München am Goetheplatz
-
-
-
-
-
Nagoya, Giappone
- National Hospital Organization Nagoya Medical Center
-
Osaka, Giappone, 540-0006
- National Hospital Organization Osaka National Hospital
-
Tokyo, Giappone, 162-0052
- Center Hospital of the National Center for Global Health and Medicine
-
-
-
-
-
Milan, Italia, 20157
- ASST Fatebenefratelli Sacco
-
Milan, Italia, 20127
- IRCCS Ospedale San Raffaele
-
Modena, Italia, 40124
- Azienda Ospedaliero-Universitaria di Modena
-
Roma, Italia, 00149
- Istituto Nazionale Malattie Infettive "Lazzaro Spallanzani" IRCCS
-
Torino, Italia, 10149
- ASL Città di Torino
-
-
-
-
PR
-
San Juan, PR, Porto Rico, 00909
- Hope Clinical Research
-
San Juan, PR, Porto Rico, 00935
- Proyecto ACTU
-
-
-
-
-
Birmingham, Regno Unito, B9 5SS
- Department of HIV & Sexual Medicine
-
Brighton, Regno Unito, BN2 3EW
- Brighton and Sussex University Hospitals NHS Trust
-
London, Regno Unito, E1 1BB.
- Barts Health NHS Trust
-
London, Regno Unito, SE5 9RS
- HIV medicine and infectious diseases
-
London, Regno Unito, SW109NH
- St.Stephen's AIDS Trust, Clinical Trials Unit, 1st Floor, St.Stephen's Centre
-
-
-
-
-
Santo Domingo, Repubblica Dominicana
- Instituto Dominicano de Estudio Virologicos - IDEV
-
-
-
-
-
Barcelona, Spagna, 08036
- Hospital Clinic Provincial de Barcelona
-
Madrid, Spagna, 28040
- Hospital Clinico San Carlos
-
Madrid, Spagna, 28046
- Hospital Universitario La Paz
-
Madrid, Spagna, 28034
- Hospital Ramon y Cajal, Madrid
-
Seville, Spagna, 4103
- Hospital Universitario Virgen del Rocio
-
-
-
-
California
-
Berkeley, California, Stati Uniti, 48072
- Be Well Medical Center
-
Beverly Hills, California, Stati Uniti, 90211
- Pacific Oaks Medical Group
-
Los Angeles, California, Stati Uniti, 90036
- Ruane Clinical Research Group, Inc
-
Oakland, California, Stati Uniti, 94609
- Alta Bates Summit Medical Center, Summit Campus, East Bay Advanced Care
-
Palm Springs, California, Stati Uniti, 92262
- Bios Clinical Research
-
San Diego, California, Stati Uniti, 92103
- University of California San Diego (UCSD)
-
Torrance, California, Stati Uniti, 90502
- Lundquist Institute for Biomedical Innovation at Harbor - UCLA Medical Center
-
West Hollywood, California, Stati Uniti, 90046
- The Men's Health Foundation
-
-
Colorado
-
Denver, Colorado, Stati Uniti, 80204
- Denver Health Medical Center
-
-
Connecticut
-
New Haven, Connecticut, Stati Uniti, 06510
- Yale University; School of Medicine; AIDS Program
-
-
Florida
-
DeLand, Florida, Stati Uniti, 32720
- Midland Florida Clinical Research Center, LLC
-
Fort Lauderdale, Florida, Stati Uniti, 33316
- Gary Richmond, MD, PA, Inc.
-
Fort Lauderdale, Florida, Stati Uniti, 33308
- Therafirst Medical Centers
-
Ft. Pierce, Florida, Stati Uniti, 34982
- Midway Immunology & Research Center, LLC
-
Miami, Florida, Stati Uniti, 33136
- Schiff Center for liver Diseases/University of Miami
-
Miami Lakes, Florida, Stati Uniti, 33016
- Floridian Clinical Research
-
Orlando, Florida, Stati Uniti, 32803
- Orlando Immunology Center
-
Orlando, Florida, Stati Uniti, 32803
- Therapeutic Concepts, PA
-
West Palm Beach, Florida, Stati Uniti, 33407
- Triple O Research Institute PA
-
-
Georgia
-
Atlanta, Georgia, Stati Uniti, 30309
- Atlanta ID Group
-
Macon, Georgia, Stati Uniti, 31201
- Mercer University School of Medicine
-
-
Illinois
-
Chicago, Illinois, Stati Uniti, 60613
- Howard Brown Health Center
-
-
Missouri
-
Kansas City, Missouri, Stati Uniti, 64111
- Kansas City Care Clinic
-
St Louis, Missouri, Stati Uniti, 63139
- Southampton Healthcare, Inc.
-
-
New Jersey
-
Newark, New Jersey, Stati Uniti, 07102
- Saint Michael's Medical Center
-
-
New Mexico
-
Santa Fe, New Mexico, Stati Uniti, 87505
- AXCES Research Group
-
-
New York
-
Flushing, New York, Stati Uniti, 11355
- New York Presbyterian Hospital
-
New York, New York, Stati Uniti, 10001
- Ricky K. Hsu, MD, PC
-
-
North Carolina
-
Chapel Hill, North Carolina, Stati Uniti, 27514
- University of North Carolina - Chapel Hill
-
Greenville, North Carolina, Stati Uniti, 27858
- East Carolina University
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, Stati Uniti, 19107
- Philadelphia FIGHT
-
-
South Carolina
-
Charleston, South Carolina, Stati Uniti, 29425
- Medical University of South Carolina (MUSC) Research NEXUS
-
-
Texas
-
Austin, Texas, Stati Uniti, 78705
- Central Texas Clinical Research
-
Bellaire, Texas, Stati Uniti, 77401
- St. Hope Foundation
-
Dallas, Texas, Stati Uniti, 75246
- North Texas Infectious Diseases Consultants
-
Dallas, Texas, Stati Uniti, 75208
- AIDS Arms, Inc., DBA Prism Health North Texas
-
Fort Worth, Texas, Stati Uniti, 76104
- Texas Centers for Infectious Disease Associates
-
Houston, Texas, Stati Uniti, 77098
- Gordon E. Crofoot MD PA
-
Longview, Texas, Stati Uniti, 75605
- Diagnostic Clinic of Longview - Center for Clinical Research
-
-
Washington
-
Seattle, Washington, Stati Uniti, 98104
- Peter Shalit, MD
-
-
-
-
-
Cape Town, Sud Africa, 7925
- Desmond Tutu Health Foundation Clinical Trials Unit
-
Ga-Rankuwa, Sud Africa, 208
- Sefako Makgatho Health Sciences University
-
Johannesburg, Sud Africa, 2193
- Ezintsha
-
-
-
-
-
Kaohsiung City, Taiwan, 80756
- Kaohsiung Medical University Chung-Ho Memorial Hospital
-
Kaohsiung City, Taiwan, 81362
- Kaohsiung Medical University Chung-Ho Memorial Hospital
-
New Taipei City, Taiwan, 22060
- Far Eastern Memorial Hospital
-
Taoyuan City, Taiwan, 33004
- Taoyuan General Hospital
-
-
Criteri di partecipazione
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Descrizione
Key Inclusion Criteria:
-
If plasma HIV-1 RNA measurements in the 6 months prior to screening are available, all levels must be < 50 copies/mL.
-
At least one documented plasma HIV-1 RNA level measured between 6 and 12 months (± 2 months) prior to screening. This and any other HIV-1 RNA measurements documented in this period must be < 50 copies/mL
-
Plasma HIV-1 RNA levels < 50 copies/mL at screening.
-
Currently receiving a complex antiretroviral (ARV) regimen due to previous viral resistance, or intolerance, or contraindication to existing single-tablet regimens (STR), and on this regimen for at least 6 months prior to the screening visit. The criteria to define a complex regimen in this study are as follows:
- A regimen containing a boosted protease inhibitor or a nonnucleos(t)ide reverse transcriptase inhibitor (NRTI) plus at least 1 other third agent (ie, an agent from a class other than NRTIs) (eg, bictegravir/emtricitabine/tenofovir alafenamide (coformulated; Biktarvy®)(BVY) + darunavir/cobicistat, BVY + etravirine), or
- A regimen of ≥ 2 pills/day, or a regimen requiring dosing more than once daily, or
- A regimen containing parenteral agent(s) (excluding a complete long-acting injectable regimen, such as intramuscular cabotegravir plus rilpivirine) as well as oral agents.
-
No documented or suspected resistance to bictegravir (BIC).
-
Estimated glomerular filtration rate ≥ 15 mL/min according to the Cockcroft-Gault formula for creatinine clearance (CLcr) who are not on renal replacement therapy.
Key Exclusion Criteria:
- Prior use of, or exposure to, lenacapavir (LEN)
- Active tuberculosis infection
- Chronic hepatitis B virus (HBV) infection
Note: Other protocol defined Inclusion/Exclusion criteria may apply.
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Trattamento
- Assegnazione: Randomizzato
- Modello interventistico: Assegnazione parallela
- Mascheramento: Nessuno (etichetta aperta)
Armi e interventi
Gruppo di partecipanti / Arm |
Intervento / Trattamento |
|---|---|
|
Sperimentale: Phase 2: Treatment Group 1: BIC 75 mg + LEN 25 mg
Participants will switch from their Stable Baseline Regimen (SBR) to a regimen of BIC 75 mg + LEN 25 mg, tablets administered orally once daily for up to 24 weeks. Participants will receive a 2-day pharmacokinetic (PK) oral loading dose of LEN 600 mg, on Days 1 and 2, in addition to the daily doses of BIC 75 mg + LEN 25 mg starting on Day 1. Participants who discontinue early or complete the Randomized Phase (RP) will have an option to continue in Extension Period (EP) |
Tablets administered orally without regard to food
Altri nomi:
Tablets administered orally without regard to food
Altri nomi:
|
|
Sperimentale: Phase 2: Treatment Group 2: BIC 75 mg + LEN 50 mg
Participants will switch from their SBR to a regimen of BIC 75 mg + LEN 50 mg, tablets administered orally once daily for up to 24 weeks. Participants will receive a 2-day PK oral loading dose of LEN 600 mg, on Days 1 and 2, in addition to the daily doses of BIC 75 mg + LEN 50 mg starting on Day 1. Participants who discontinue early or complete the RP will have an option to continue in EP. |
Tablets administered orally without regard to food
Altri nomi:
Tablets administered orally without regard to food
Altri nomi:
|
|
Comparatore attivo: Phase 2: Treatment Group 3: SBR
Participants will continue with their SBR for up to 24 weeks. Participants who discontinue early or complete the RP will have an option to continue in EP. |
SBR will include a combination of antiretroviral (ARV) regimen. ARV regimen may include the following, except for participants taking a single tablet regimen or taking a complete parenteral regimen (Cabenuva).
|
|
Sperimentale: Phase 3: Treatment Group 1: BIC/LEN 75 mg/50 mg FDC
Participants will switch from their SBR to a regimen of BIC/LEN 75mg/50mg FDC, administered orally once daily for up to 48 weeks. Participants will receive a 2-day PK oral loading dose of LEN 600 mg, on Days 1 and 2, in addition to the daily doses of BIC/LEN 75 mg/50 mg FDC starting on Day 1. Participants who discontinue early or complete the RP will have an option to continue in EP. |
Tablets administered orally without regard to food
Altri nomi:
|
|
Comparatore attivo: Phase 3: Treatment Group 2: SBR
Participants will continue with their SBR for up to 48 weeks. Participants who will discontinue early or complete the RP had an option to continue in EP. |
SBR will include a combination of antiretroviral (ARV) regimen. ARV regimen may include the following, except for participants taking a single tablet regimen or taking a complete parenteral regimen (Cabenuva).
|
|
Sperimentale: Phase 2/Phase 3:BIC/LEN 75/50 mg FDC
At the end of randomized treatment, participants in Phase 2 and Phase 3 treatment groups who discontinue early or complete the RP will be given an option to enter in EP and will receive BIC/LEN 75/50 mg FDC until the drug is available in market or Gilead elects to withdraw the study. Participants in the SBR groups (Phase 2 Treatment Group 3 and Phase 3 Treatment Group 2 will also receive a 2-day PK oral loading dose of LEN 600 mg, on Days 1 and 2 of EP). |
Tablets administered orally without regard to food
Altri nomi:
Tablets administered orally without regard to food
Altri nomi:
|
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Phase 2: Percentage of Participants With Human Immunodeficiency Virus-1 Ribonucleic Acid (HIV-1 RNA) ≥ 50 Copies/mL at Week 24 as Determined by the United States Food and Drug Administration (US FDA) Defined Snapshot Algorithm
Lasso di tempo: Week 24
|
Participants who had the last available on-treatment HIV-1 RNA≥ 50 copies/mL in the week 24 analysis window, or who did not have on-treatment HIV-1 RNA data in the week 24 analysis window and participants who discontinued study drug prior to or in the week 24 analysis window due to lack of efficacy, or who discontinued study drug prior to or in the week 24 analysis window due to adverse event (AE) or death and have the last available on-treatment HIV-1 RNA≥ 50 copies/mL, or who discontinued study drug prior to or in the week 24 analysis window due to reasons other than AE, death, or lack of efficacy and have the last available on-treatment HIV-1 RNA ≥ 50 copies/mL were included. The Week 24 window for snapshot algorithm was between Days 127 and 210 (inclusively). Percentages were rounded off. |
Week 24
|
|
Phase 3: Percentages of Participants With HIV-1 RNA ≥ 50 Copies/mL at Week 48 as Determined by the US FDA-defined Snapshot Algorithm
Lasso di tempo: Week 48
|
Participants who had the last available on-treatment HIV-1 RNA ≥ 50 copies/mL in the Week 48 analysis window, or who did not have on-treatment HIV-1 RNA data in the Week 48 analysis window and who discontinued study drug prior to or in the Week 48 analysis window due to lack of efficacy, or who discontinued study drug prior to or in the Week 48 analysis window due to AE or death and have the last available on-treatment HIV-1 RNA ≥ 50 copies/mL, or who discontinued study drug prior to or in the Week 48 analysis window due to reasons other than AE, death, or lack of efficacy and have the last available on-treatment HIV-1 RNA ≥ 50 copies/mL were included. The Week 48 window for snapshot algorithm was between Days 295 and 378 (inclusively). Percentages were rounded off. |
Week 48
|
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Phase 2: Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 24 as Determined by the US FDA-defined Snapshot Algorithm
Lasso di tempo: Week 24
|
Participants who had the last available on-treatment HIV-1 RNA < 50 copies/mL in the Week 24 analysis window were included. The Week 24 window for snapshot algorithm was between Days 127 and 210 (inclusively). Percentages were rounded off. |
Week 24
|
|
Phase 2: Change From Baseline in Clusters of Differentiation 4 (CD4) Cell Count at Week 24
Lasso di tempo: Baseline, Week 24
|
Baseline, Week 24
|
|
|
Phase 2: Percentage of Participants Experiencing Treatment-Emergent Adverse Events (TEAEs) Through Week 24
Lasso di tempo: First dose date up to Week 24
|
An adverse event (AE) was any untoward medical occurrence in a clinical study participant administered a study drug that did not necessarily had a causal relationship with the treatment. TEAEs were defined as any AE that begins on or after the date of first dose of study drug up to the date of last dose of study drug plus 60 days (for BIC+LEN or BIC/LEN FDC) or 30 days (for SBR) or any AE leading to study drug discontinuation. Percentages were rounded off. |
First dose date up to Week 24
|
|
Phase 2: PK Parameter: Cmax for Bictegravir (BIC) at Steady State
Lasso di tempo: At Week 16 or 24
|
Cmax is defined as the maximum observed concentration of drug. Participants chose to participate at either Week 16 or Week 24 visit as the steady state visit. |
At Week 16 or 24
|
|
Phase 2: PK Parameter: Cmax for Lenacapavir (LEN) at Steady State
Lasso di tempo: At Week 16 or Week 24
|
Cmax is defined as the maximum observed concentration of drug. Participants chose to participate at either Week 16 or Week 24 visit as the steady state visit. |
At Week 16 or Week 24
|
|
Phase 2: PK Parameter: AUCtau of BIC at Steady State
Lasso di tempo: At Week 16 or 24
|
AUCtau is defined as the area under the concentration versus time curve over the dosing interval. Participants chose to participate at either Week 16 or Week 24 visit as the steady state visit. |
At Week 16 or 24
|
|
Phase 2: PK Parameter: AUCtau for LEN at Steady State
Lasso di tempo: At Week 16 or Week 24
|
AUCtau is defined as the area under the concentration versus time curve over the dosing interval. Participants chose to participate at either Week 16 or Week 24 visit as the steady state visit. |
At Week 16 or Week 24
|
|
Phase 2: PK Parameter: Ctrough of BIC at Steady State
Lasso di tempo: At Week 16 or Week 24
|
Ctrough is defined as the observed drug concentration at the end of the dosing interval. Participants chose to participate at either Week 16 or Week 24 visit as the steady state visit. |
At Week 16 or Week 24
|
|
Phase 2: PK Parameter: Ctrough of LEN at Steady State
Lasso di tempo: At Week 16 or Week 24
|
Ctrough is defined as the observed drug concentration at the end of the dosing interval. Participants chose to participate at either Week 16 or Week 24 visit as the steady state visit. |
At Week 16 or Week 24
|
|
Phase 3: Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 48 as Determined by the US FDA-defined Snapshot Algorithm
Lasso di tempo: Week 48
|
Participants who had the last available on-treatment HIV-1 RNA < 50 copies/mL in the Week 48 analysis window were included. The Week 48 window for snapshot algorithm was between Days 295 and 378 (inclusively). |
Week 48
|
|
Phase 3: Change From Baseline in CD4 Cell Count at Week 48
Lasso di tempo: Baseline, Week 48
|
An AE was any untoward medical occurrence in a clinical study participant administered a study drug that did not necessarily had a causal relationship with the treatment. TEAEs were defined as any AE that begins on or after the date of first dose of study drug up to the date of last dose of study drug plus 60 days (for BIC+LEN or BIC/LEN FDC) or 30 days (for SBR) or any AE leading to study drug discontinuation. Percentages were rounded off. |
Baseline, Week 48
|
|
Phase 3: Percentage of Participants Experiencing TEAEs Through Week 48
Lasso di tempo: First dose date up to Week 48
|
An AE was any untoward medical occurrence in a clinical study participant administered a study drug that did not necessarily had a causal relationship with the treatment. TEAEs were defined as 1 or both of the following: Any AEs leading to premature discontinuation of study drug, or any AEs with an onset date on or after the study drug start date and no later than the last exposure date after permanent discontinuation of the study drug. Percentages were rounded off. |
First dose date up to Week 48
|
|
Phase 3 Treatment Group 1: (BIC/LEN 75 mg/50 mg FDC): Percentage of Participants With HIV-1 RNA ≥ 50 Copies/mL at Week 96 as Determined by the US FDA-defined Snapshot Algorithm
Lasso di tempo: Week 96
|
Week 96
|
|
|
Phase 3 Treatment Group 1: (BIC/LEN 75 mg/50 mg FDC): Percentage of Participants With HIV-1 RNA ≥ 50 Copies/mL at Week 144 as Determined by the US FDA-defined Snapshot Algorithm
Lasso di tempo: Week 144
|
Week 144
|
|
|
Phase 3 Treatment Group 1: (BIC/LEN 75 mg/50 mg FDC): Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 96 as Determined by the US FDA-defined Snapshot Algorithm
Lasso di tempo: Week 96
|
Week 96
|
|
|
Phase 3 Treatment Group 1: (BIC/LEN 75 mg/50 mg FDC): Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 144 as Determined by the US FDA-defined Snapshot Algorithm
Lasso di tempo: Week 144
|
Week 144
|
|
|
Phase 3 Treatment Group 1: (BIC/LEN 75 mg/50 mg FDC): Change From Baseline in CD4 Cell Count at Week 96
Lasso di tempo: Baseline, Week 96
|
Baseline, Week 96
|
|
|
Phase 3 Treatment Group 1: (BIC/LEN 75 mg/50 mg FDC): Change From Baseline in CD4 Cell Count at Week 144
Lasso di tempo: Baseline, Week 144
|
Baseline, Week 144
|
|
|
Phase 3 Treatment Group 1: (BIC/LEN 75 mg/50 mg FDC): Percentage of Participants Experiencing TEAEs Through Week 96
Lasso di tempo: Week 96
|
Week 96
|
|
|
Phase 3 Treatment Group 1: (BIC/LEN 75 mg/50 mg FDC): Percentage of Participants Experiencing TEAEs Through Week 144
Lasso di tempo: Week 144
|
Week 144
|
Collaboratori e investigatori
Sponsor
Pubblicazioni e link utili
Pubblicazioni generali
- Arora P, Hindman JT, West S, Ling J, Palaparthy R, Marathe DD. The effect of antacid and mineral supplements on bictegravir pharmacokinetics: results from a Phase 1, open-label, drug-drug interaction study. Antimicrob Agents Chemother. 2026 Jan 7;70(1):e0078125. doi: 10.1128/aac.00781-25. Epub 2025 Nov 28.
- Orkin C, Ruane PJ, Hedgcock M, Gaultier C, Losso MH, Trottier B, Lutz T, O'Reilly M, Bloch M, Slim J, Ramgopal M, Sokhela S, Mounzer K, Tsai HC, Santana Bagur J, Zhang X, Aizen K, Price K, Margot N, Montezuma-Rusca JM, Sklar P, Rhee M, Cahn P; ARTISTRY-1 Study Group. Switch to single-tablet bictegravir-lenacapavir from a complex HIV regimen (ARTISTRY-1): a randomised, open-label, phase 3 clinical trial. Lancet. 2026 Mar 28;407(10535):1249-1258. doi: 10.1016/S0140-6736(26)00307-7. Epub 2026 Feb 25.
- Ph2 PK data was included as part of the 2024 HIV-G presentation: https://hivglasgow.org/wp-content/uploads/2025/02/P049_Arora.pdf
Collegamenti utili
Studiare le date dei record
Studia le date principali
Inizio studio (Effettivo)
Completamento primario (Effettivo)
Completamento dello studio (Stimato)
Date di iscrizione allo studio
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Effettivo)
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Termini MeSH pertinenti aggiuntivi
Altri numeri di identificazione dello studio
- GS-US-621-6289
- 2022-500929-33 (Altro identificatore: European Medicines Agency)
- DOH-27-052023-8574 (Altro identificatore: South African Clinical Trial Registry)
- jRCT2051230168 (Altro identificatore: Japan registry)
Piano per i dati dei singoli partecipanti (IPD)
Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .